Pesquisa: Tirzepatide

Dual GIP/GLP-1 receptor agonist for superior weight loss

Tirzepatide Once Weekly for the Treatment of Obesity

N Engl J Med 2022 600 Clinical Trial

SURMOUNT-1: In 2,539 adults with obesity, once-weekly tirzepatide (GIP/GLP-1 dual agonist) achieved substantial sustained weight loss over 72 weeks.